SLCO1B1 and myopathy: On the therapeutic side,pharmacogenomic testing, for example genotyping for CYP2C19 to guide antiplatelet selection or screening for SLCO1B1 to reduce the riskof statin myopathy, translates laboratory discoveries into individualized drug choice and dosing [12].Together, these modalities form a unified platform that enhances risk assessment, diagnosis and personalized therapy in moderncardiovascular medicine.